Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis-Reference-Cited by-同舟云学术

Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis

Published:2017-06-20 Issue:6 Volume:12 Page:e0179602
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Sikic Danijel^ORCID,Keck Bastian,Wach Sven,Taubert Helge,Wullich Bernd,Goebell Peter J.,Kahlmeyer Andreas,Olbert Peter,Isfort Philipp,Nimphius Wilhelm,Hartmann Arndt,Giedl Johannes,

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference32 articles.

1. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update;M Rouprêt;Eur Urol,2015

2. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients;MC Hall;Urology,1998

3. Upper tract urothelial carcinoma: current treatment and outcomes;BT Ristau;Urology,2012

4. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma;JJ Leow;Eur Urol,2014

5. Optimal treatment for metastatic bladder cancer;EM Carballido;Curr Oncol Rep,2014

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A deep‐learning workflow to predict upper tract urothelial carcinoma protein‐based subtypes from H&E slides supporting the prioritization of patients for molecular testing;The Journal of Pathology: Clinical Research;2024-03

2. Complete remission following pembrolizumab therapy for a patient with nephroureterectomy positive-margin carcinoma in situ and bladder cancer unresponsive to Bacille Calmette–Guérin therapy;SAGE Open Medical Case Reports;2023-01

3. The difference between cytokeratin 20 expression in high- and low-grade urothelial bladder carcinomas: A cross-sectional study;Urology Annals;2023

4. Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation;International Journal of Molecular Sciences;2022-07-16

5. Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression;International Journal of Molecular Sciences;2022-07-15